<div id="readability-page-1"><p>Roth MKM analyst Boobalan Pachaiyappan initiated coverage with a Buy rating on Ovid Therapeutics today and set a price target of $3.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Pachaiyappan is a 4-star analyst with an average return of <span>18.8%</span> and a 48.21% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, CervoMed, and PolyPid.</p> <p>Ovid Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.67.</p></div>

OVID

<p>Roth MKM analyst Boobalan Pachaiyappan initiated coverage on Ovid Therapeutics with a Buy rating and a price target of $3.00. Pachaiyappan, a 4-star analyst with an average return of 18.8%, covers the Healthcare sector. Ovid Therapeutics has a consensus Strong Buy rating and a price target consensus of $4.67.</p>

Ovid Therapeutics (OVID) Gets a Buy from Roth MKM